نتائج البحث - "Paul Germonpré"

المساهمون: CCA - Cancer biology and immunology, Medical oncology laboratory, Medical oncology, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism

المصدر: Van Der Steen, N, Mentens, Y, Ramael, M, Leon, L G, Germonpré, P, Ferri, J, Gandara, D R, Giovannetti, E, Peters, G J, Pauwels, P & Rolfo, C 2018, ' Double Trouble : A Case Series on Concomitant Genetic Aberrations in NSCLC ', Clinical Lung Cancer, vol. 19, no. 1, pp. 35-41 . https://doi.org/10.1016/j.cllc.2017.06.010Test
Clinical Lung Cancer, 19(1), 35-41. Elsevier
Clinical lung cancer

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Viral Oncogene, medicine.disease_cause, Targeted therapy, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Exon, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Genetic Testing, Molecular Targeted Therapy, Epidermal growth factor receptor, Neoplasm Metastasis, Lung cancer, Genetic testing, biology, medicine.diagnostic_test, business.industry, Middle Aged, Proto-Oncogene Proteins c-met, medicine.disease, ErbB Receptors, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Cancer research, biology.protein, Female, Human medicine, KRAS, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::184d2225d523195834ff5aba158882edTest
https://doi.org/10.1016/j.cllc.2017.06.010Test

6

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

المؤلفون: Marcello Tiseo, Godefridus J. Peters, Paul Germonpré, Christian Rolfo, Nele Van Der Steen, Christophe Hermans, Giulia Mazzaschi, Elisa Giovannetti, Karen Zwaenepoel, Daan P. Geerke, Patrick Pauwels, Paul Van Schil, Ken Op de Beeck, Filip Lardon, Rosa A. Luirink

المساهمون: Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Imaging and biomarkers, AIMMS, Molecular and Computational Toxicology

المصدر: Molecules
Volume 24
Issue 24
Molecules: a journal of synthetic chemistry and natural product chemistry
Molecules, 24(24). Multidisciplinary Digital Publishing Institute
van der Steen, N, Zwaenepoel, K, Mazzaschi, G, A Luirink, R, P Geerke, D, op de Beeck, K, Hermans, C, Tiseo, M, van Schil, P, Lardon, F, Germonpré, P, Rolfo, C, Giovannetti, E, J Peters, G & Pauwels, P 2019, ' The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies ', Molecules, vol. 24, no. 24 . https://doi.org/10.3390/molecules24244443Test
Molecules, 24(24):4443. Multidisciplinary Digital Publishing Institute (MDPI)
Van Der Steen, N, Zwaenepoel, K, Mazzaschi, G, Luirink, R A, Geerke, D P, De Beeck, K O, Hermans, C, Tiseo, M, Van Schil, P, Lardon, F, Germonpré, P, Rolfo, C, Giovannetti, E, Peters, G J & Pauwels, P 2019, ' The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer : Two new mutations warrant further studies ', Molecules, vol. 24, no. 24, 4443 . https://doi.org/10.3390/molecules24244443Test

مصطلحات موضوعية: Male, Lung Neoplasms, Mutant, Pharmaceutical Science, NSCLC, Analytical Chemistry, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Drug Discovery, Epidermal growth factor receptor, Neoplasm Metastasis, Receptor, 0303 health sciences, biology, Middle Aged, Proto-Oncogene Proteins c-met, 3. Good health, ErbB Receptors, Gene Expression Regulation, Neoplastic, Chemistry, Chemistry (miscellaneous), 030220 oncology & carcinogenesis, Molecular Medicine, Biomarker (medicine), Female, Antibody, Adult, C-Met, EGFR, Article, Deep sequencing, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Biomarkers, Tumor, medicine, Humans, Physical and Theoretical Chemistry, Lung cancer, Biology, Aged, 030304 developmental biology, business.industry, Organic Chemistry, Gene Amplification, medicine.disease, chemistry, Drug Resistance, Neoplasm, Mutation, biology.protein, Cancer research, Tumor Suppressor Protein p53, business, Biomarkers

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41c017861e5a2eba24b3519c13c0ba8Test
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076355617&origin=inwardTest

7

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

المصدر: Annals of Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Thoracic Tumors, Population, lefitolimod, law.invention, Carboplatin, Maintenance Chemotherapy, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Randomized controlled trial, law, TLR9 agonist, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, education, Survival rate, Etoposide, education.field_of_study, business.industry, Hazard ratio, Cancer, International Agencies, SCLC, Hematology, Original Articles, medicine.disease, Prognosis, Chemotherapy regimen, Small Cell Lung Carcinoma, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Toll-Like Receptor 9, immunotherapy, Cisplatin, business, Immunosuppressive Agents, Leflunomide, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56efb37cb887fb530c467815672b714cTest
https://pubmed.ncbi.nlm.nih.gov/30137193Test

8

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

المؤلفون: Paul Germonpré, Tim Van den Wyngaert

المصدر: PLoS ONE
PLoS ONE, Vol 14, Iss 4, p e0215135 (2019)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Lung Neoplasms, Maximum Tolerated Dose, Science, non-small cell lung cancer (NSCLC), Salvage therapy, Adenocarcinoma of Lung, Antineoplastic Agents, Pemetrexed, Gastroenterology, 03 medical and health sciences, Erlotinib Hydrochloride, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Survival rate, Aged, Platinum, Salvage Therapy, Multidisciplinary, business.industry, Middle Aged, medicine.disease, Prognosis, Rash, Survival Rate, Tolerability, 030220 oncology & carcinogenesis, Medicine, Female, Erlotinib, medicine.symptom, business, Engineering sciences. Technology, medicine.drug, Follow-Up Studies

وصف الملف: pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b5ffe88687fd12a96624df438aa3d9Test
https://pubmed.ncbi.nlm.nih.gov/30973926Test

9

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

المؤلفون: Djordje Atanackovic, M. Feurer, Jaafar Bennouna, Martin Picard, Eray Goekkurt, Kenneth J. O'Byrne, Maciej Krzakowski, J. Straub, Hervé Lena, Paul Germonpré, Dennis Verhoeven, Wolfgang Schuette, Janusz Milanowski, Christine Hicking, C. F Waller, Aleksandra Szczesna, C. Gridelli, Johan Vansteenkiste, Fabrice Barlesi

المصدر: Annals of Oncology. 26:1734-1740

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Lung Neoplasms, Cetuximab, Phases of clinical research, non-small cell lung cancer (NSCLC), Cilengitide, Adenocarcinoma, Vinblastine, Deoxycytidine, Disease-Free Survival, chemistry.chemical_compound, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Receptors, Vitronectin, Progression-free survival, Lung cancer, Aged, Proportional Hazards Models, Aged, 80 and over, business.industry, Hazard ratio, Vinorelbine, Hematology, Middle Aged, Integrin alphaVbeta3, Prognosis, medicine.disease, Gemcitabine, Chemotherapy regimen, ErbB Receptors, Treatment Outcome, chemistry, Carcinoma, Squamous Cell, Female, Cisplatin, business, Snake Venoms, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34759ab79cb49f71af02421a4c21b994Test
https://doi.org/10.1093/annonc/mdv219Test

10

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

المساهمون: Gerber, D, Horn, L, Boyer, M, Sanborn, R, Natale, R, Palmero, R, Bidoli, P, Bondarenko, I, Germonpre, P, Ghizdavescu, D, Kotsakis, A, Lena, H, Losonczy, G, Park, K, Su, W, Tang, M, Lai, J, Kallinteris, N, Shan, J, Reck, M, Spigel, D

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Subset Analysis, Oncology, medicine.medical_specialty, Lung Neoplasms, Bavituximab, medicine.medical_treatment, Docetaxel, Adenocarcinoma, Placebo, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Prospective Studies, Lung cancer, Aged, Aged, 80 and over, Salvage Therapy, Chemotherapy, business.industry, Antibodies, Monoclonal, Original Articles, Hematology, Middle Aged, Prognosis, medicine.disease, Chemotherapy regimen, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7b58c1ff58194f0d3dbc26722f5ebcTest
http://hdl.handle.net/10281/260656Test

تنقيح النتائج